Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) has provided an update.
On November 20, 2025, Genmab A/S announced the grant of 6,933 restricted stock units and 7,377 warrants to its employees and subsidiaries. These grants are part of Genmab’s compensation strategy to incentivize and retain talent, with the restricted stock units and warrants vesting over a period of three years. This move underscores Genmab’s commitment to aligning employee interests with company growth and enhancing its competitive positioning in the biotechnology industry.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a strong presence across North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies, aiming to transform the lives of people with cancer and other serious diseases by 2030.
Average Trading Volume: 2,129,239
Technical Sentiment Signal: Buy
Current Market Cap: $18.79B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.